Eculizumab is a recombinant human IgG2/4_ monoclonal antibody used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Eculizumab acts as a terminal complement inhibitor that binds to the terminal complement component 5, or C5 and suppresses the complement cascade.